Background: Although the recommended first line treatment for JIA, up to 50% of children will not respond to MTX. Currently, it is not possibly to identify at the start of therapy which children will not respond and thus initiation of effective therapies may be delayed. Aims: The aim of this analysis was to identify clinical factors measured at the outset of therapy associated with non-response to MTX with a view towards building an accurate multifactorial prediction model. Methods: Children with JIA treated with MTX were identified from four large multi-centre UK observational studies participating in the Childhood Arthritis Response to Treatment (CHART) consortium: Childhood Arthritis Prospective Study, British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study, Biologics for Children with Rheumatic Diseases Study, and Childhood Arthritis Response to Medication Study. Demographic, clinical and laboratory variables at start of MTX and at 6 (4-12) months following treatment start were extracted and combined using a common data model. Nonresponse at 6-months was defined as lack of achievement of the ACR Pediatric (ACR Pedi) 30 criteria or initiation of biologics due to MTX inefficacy. Patients stopping MTX prematurely (< 4 months) due to intolerance were excluded. Each potential predictor of non-response was evaluated using logistic regression. Significant factors were taken into a multivariate logistic regression model and estimated using
Background: The anti-synthestase autoantibody is the most common in adult patients with dermatomyositis (DM) 1 . In the pediatric population, anti-synthetase autoantibodies are rare and found in less than 16. 
